诺华肢端肥大症药物Signifor LAR(Pasireotide for Injectable Suspension, for Intramuscular Use)获欧盟批准 2014年11月25日,欧盟委员会(EC)已批准Signifor LAR(pasireotide,帕瑞肽),用于不适合手术治疗或尚未治愈以及第一代生长抑素类似物(SSA)控制不佳的肢端肥大症(acromegaly)成人患者的治疗。Signifor LAR是新一代长效缓释剂型Signifor,每月肌肉注射(IM)一次,该药为第一代SSA控制不佳的肢端肥大症患者提供了首个可供选择的治疗方案。 Signifor LAR的获批,是基于2项多中心III期研究(C2402和C2305)的数据。2项研究结果均表明,与第一代生长抑素类似物(奥曲肽LAR或兰瑞肽Autogel)治疗组相比,Signifor LAR治疗组有更多的患者显著实现了生化控制(通过GH和IGF-1水平测定)。此前,Signifor LAR已于2014年9月获得欧洲药品管理局(EMA)人用医药产品委员会(CHMP)建议批准的积极意见。 在欧盟,肢端肥大症发病率约为万分之一至二。肢端肥大症(acromegaly)由脑垂体中的良性(非癌性)肿瘤导致生长激素的过量分泌,引发胰岛素样生长因子1(IGF-1)水平升高。GH和IGF-1水平升高的综合效应,导致身体部分部位(包括手、脚、面部)扩大,并伴有严重的并发症,如心血管疾病、代谢性疾病和呼吸系统疾病。如果暴露于长期高水平的GH和IGF-1,患者死亡风险将升高2-3倍。 肢端肥大症治疗的主要目标是疾病的生化控制,由GH和IGF-1水平评测。其他的疾病管理目标包括肿瘤的缩小和临床症状和体征的改善。 Signifor(帕瑞肽)是一种多受体靶向生长抑素类似物,能够高亲和力结合5种促生长素抑制素受体亚型中的4种(sst1,2,3,5)。目前该药已获FDA批准用于不适合垂体手术或尚未治愈的库欣病(Cushing's disease)成人患者的治疗。同时,Signifor已获欧盟批准,用于不适合手术或手术失败的库欣病成人患者的治疗。Signifor每天2次皮下注射(SC)。 Signifor LAR则是一种长效缓释(LAR)每月一次肌肉注射(IM)剂型的Signifor。目前,诺华也已向美国及其他国家提交了Signifor LAR治疗肢端肥大症的监管申请。 www.oneyao.net Information Generic Name: pasireotide Trade Name: Signifor LAR Synonym: SOM 230 Entry Type: New formulation Development and Regulatory status UK: Phase III Clinical Trials EU: Phase III Clinical Trials US: Phase III Clinical Trials UK launch Plans: Available only to registered users Actual UK launch date: Comments Orphan designation (EU/3/09/671) was granted by the European Commission to Novartis for pasireotide for treatment of Cushing’s disease in Oct 09 [5]. 13/02/2015 10:27:05 Apr 14: Filings now delayed until 2016 [4]. 18/06/2014 15:17:03 Jan 14: Filings still planned for 2015 [3]. 01/05/2014 11:17:39 Mar 13: Filings planned 2015 [2]. 05/03/2013 09:45:04 Nov 11: PIII study started [1]. 09/03/2012 19:30:17 Trial or other data NCT01374906 a PIII double-blind, multicenter, RCT of monthly IM pasireotide (LAR) in 148 patients with Cushing´s disease. The primary outcome is the proportion of responders after 7 months treatment (defined as patients who attain Mean Urinary Free Cortisol (mUFC) ≤ 1.0 X Upper Limit of Normal (ULN) regardless of dose-titration). Patients will receive pasireotide LAR 10mg or 30mg once every 28 days for 4 months, followed by dose up-titration or starting dose continuation. Patients considered suitable for surgery are excluded. The study started Nov 11 and is due to complete Nov 15 [1]. 09/03/2012 19:32:21 References Available only to registered users Category BNF Category: Endocrine system (06) Pharmacology: Multireceptor targeting somatostatin analog (SSA) that binds with high affinity to four of the five somatostatin receptor subtypes (sst 1, 2, 3 and 5) Epidemiology: Endogenous hypercortisolism affects around 0.6 in 10,000 people in the EU; corticotropin-dependent causes account for about 80–85% of cases, and of these, 80% are due to pituitary adenomas with the rest due to ectopic corticotropin syndrome. Indication: Cushing's disease Additional Details: first-line, monthly IM injection Method(s) of Administration Intramuscular Company Information Name: Novartis US Name: Novartis Further Information Anticipated commissioning route (England) NHSE High cost drug list? Yes Tariff Not routinely commissioned by NHSE - IFR approval [6] Implications Available only to registered users |
肢端肥大症长效药物Signifor LAR注射剂获欧盟批准简介:
诺华肢端肥大症药物Signifor LAR(Pasireotide for Injectable Suspension, for Intramuscular Use)获欧盟批准2014年11月25日,欧盟委员会(EC)已批准Signifor LAR(pasireotide,帕瑞肽),用于不适合手 ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多 |